Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures

Experimental Eye Research

Volumn 116, Issue , 2013, Pages 96-108

  Gorham, Ronald D ^a   Forest, David L ^b   Tamamis, Phanourios ^c   López de Victoria, Aliana ^a   Kraszni, Márta ^d   Kieslich, Chris A ^a   Banna, Christopher D ^b   Bellows Peterson, Meghan L ^e   Larive, Cynthia K ^d   Floudas, Christodoulos A ^e   Archontis, Georgios ^c   Johnson, Lincoln V ^b   Morikis, Dimitrios ^a  

^a University of California Riverside   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CYPRUS   (Cyprus)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Princeton University   (United States)

Author keywords

AMD; AP; ApoE; C3; C3b; C3c; C5b 9; Complement inhibitors; Complement system; Compstatin family peptides; Drusen; ELISA; FB; Macular degeneration; MD; Molecular dynamics; PDB; Retinal pigmented epithelium; RP HPLC; RPE

Indexed keywords

ARGININE; COMPLEMENT COMPONENT C3; COMPSTATIN; PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; BIOGENESIS; CELL CULTURE; COMPLEMENT ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SOLUBILITY; DRUSEN; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPOPHILICITY; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PEPTIDE SYNTHESIS; PIGMENT CELL; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; RETINA MACULA AGE RELATED DEGENERATION;

AGE-RELATED MACULAR DEGENERATION; ALTERNATIVE PATHWAY OF COMPLEMENT ACTIVATION; AMD; AP; APOE; APOLIPOPROTEIN E; C3; C3B; C3C; C5B-9; COMPLEMENT INHIBITORS; COMPLEMENT SYSTEM; COMPLEMENT SYSTEM PROTEIN 3; COMPSTATIN FAMILY PEPTIDES; DRUSEN; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR B; FB; MACULAR DEGENERATION; MD; MOLECULAR DYNAMICS; PDB; PROTEIN DATA BANK; RETINAL PIGMENTED EPITHELIUM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RP-HPLC; RPE; THE B-FRAGMENT OF C3; THE C-FRAGMENT OF C3; THE MEMBRANE ATTACK COMPLEX CONSISTING OF COMPLEMENT PROTEINS C5B, C6, C7, C8, AND C9(N);

CELLS, CULTURED; COMPLEMENT ACTIVATION; HUMANS; PEPTIDES, CYCLIC; RETINAL DRUSEN; RETINAL PIGMENT EPITHELIUM;

EID: 84884385236     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2013.07.023     Document Type: Article

References (57)

1. Anderson D.H., Ozaki S., Nealon M., Neitz J., Mullins R.F., Hageman G.S., Johnson L.V. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: Implications for the process of drusen formation. Am. J. Ophthalmol. 2001, 131:767-781.
2. Anderson D.H., Radeke M.J., Gallo N.B., Chapin E.A., Johnson P.T., Curletti C.R., Hancox L.S., Hu J., Ebright J.N., Malek G., Hauser M.A., Rickman C.B., Bok D., Hageman G.S., Johnson L.V. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res. 2010, 29:95-112.
3. Bellows M.L., Fung H.K., Taylor M.S., Floudas C.A., López de Victoria A., Morikis D. New compstatin variants through two de novo protein design frameworks. Biophys. J. 2010, 98:2337-2346.
4. Bellows M.L., Taylor M.S., Cole P.A., Shen L., Siliciano R.F., Fung H.K., Floudas C.A. Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. Biophys. J. 2010, 99:3445-3453.
5. Bellows-Peterson M.L., Fung H.K., Floudas C.A., Kieslich C.A., Zhang L., Morikis D., Wareham K.J., Monk P.N., Hawksworth O.A., Woodruff T.M. De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation. J.Med. Chem. 2012, 55:4159-4168.
6. Berthod A., Carda-Broch S. Determination of liquid-liquid partition coefficients by separation methods. J.Chromatogr. A 2004, 1037:3-14.
7. Brooks B.R., Brooks C.L., Mackerell A.D., Nilsson L., Petrella R.J., Roux B., Won Y., Archontis G., Bartels C., Boresch S., Caflisch A., Caves L., Cui Q., Dinner A.R., Feig M., Fischer S., Gao J., Hodoscek M., Im W., Kuczera K., Lazaridis T., Ma J., Ovchinnikov V., Paci E., Pastor R.W., Post C.B., Pu J.Z., Schaefer M., Tidor B., Venable R.M., Woodcock H.L., Wu X., Yang W., York D.M., Karplus M. CHARMM: the biomolecular simulation program. J.Comput. Chem. 2009, 30:1545-1614.
8. CAPT Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial. Ophthalmology 2008, 115:1474-1479. 1479 e1471-1476.
9. Chi Z.L., Yoshida T., Lambris J.D., Iwata T. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv. Exp. Med. Biol. 2010, 703:127-135.
10. Furlong S.T., Dutta A.S., Coath M.M., Gormley J.J., Hubbs S.J., Lloyd D., Mauger R.C., Strimpler A.M., Sylvester M.A., Scott C.W., Edwards P.D. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles. Immunopharmacology 2000, 48:199-212.
11. Hageman G.S., Luthert P.J., Chong N.H.V., Johnson L.V., Anderson D.H., Mullins R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 2001, 20:705-732.
12. Henchoz Y., Bard B., Guillarme D., Carrupt P.A., Veuthey J.L., Martel S. Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution. Anal. Bioanal. Chem. 2009, 394:707-729.
13. Humphrey W., Dalke A., Schulten K. VMD: Visual molecular dynamics. J.Mol. Graphics 1996, 14:33-38.
14. Hwang T.L., Shaka A.J. Water suppression that works - excitation sculping using arbitrary wave-forms and pulsed-field gradients. J.Magn. Reson. Ser. A 1995, 112:275-279.
15. Im W., Lee M.S., Brooks C.L. Generalized born model with a simple smoothing function. J.Comput. Chem. 2003, 24:1691-1702.
16. Janssen B.J., Halff E.F., Lambris J.D., Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J.Biol. Chem. 2007, 282:29241-29247.
17. Johnson L.V., Forest D.L., Banna C.D., Radeke C.M., Maloney M.A., Hu J., Spencer C.N., Walker A.M., Tsie M.S., Bok D., Radeke M.J., Anderson D.H. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. PNatl. Acad. Sci. USA 2011, 108:18277-18282.
18. Katragadda M., Magotti P., Sfyroera G., Lambris J.D. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J.Med. Chem. 2006, 49:4616-4622.
19. Kieslich C.A., Tamamis P., Gorham R.D.J., López de Victoria A., Sausman N., Archontis G., Morikis D. Exploring protein-ligand and protein-protein interactions in the immune system using molecular dynamics and continuum electrostatics. Curr. Phys. Chem. 2012, 2:324-343.
20. Klein M.L., Ferris F.L., Armstrong J., Hwang T.S., Chew E.Y., Bressler S.B., Chandra S.R. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology 2008, 115:1026-1031.
21. Klepeis J.L., Floudas C.A., Morikis D., Tsokos C.G., Argyropoulos E., Spruce L., Lambris J.D. Integrated computational and experimental approach for lead optimization and design of compstatin variants with improved activity. J.Am. Chem. Soc. 2003, 125:8422-8423.
22. Klepeis J.L., Floudas C.A., Morikis D., Tsokos C.G., Lambris J.D. Design of peptide analogues with improved activity using a novel de novo protein design approach. Ind. Eng. Chem. Res. 2004, 43:3817-3826.
23. Krivov G.G., Shapovalov M.V., Dunbrack R.L. Improved prediction of protein side-chain conformations with SCWRL4. Proteins 2009, 77:778-795.
24. López de Victoria A., Gorham R.D., Bellows-Peterson M.L., Ling J., Lo D.D., Floudas C.A., Morikis D. Anew generation of potent complement inhibitors of the compstatin family. Chem. Biol. Drug Des. 2011, 77:431-440.
25. Macias A.T., MacKerell A.D. CH/pi interactions involving aromatic amino acids: refinement of the CHARMM tryptophan force field. J.Comput. Chem. 2005, 26:1452-1463.
26. MacKerell A.D., Bashford D., Bellott M., Dunbrack R.L., Evanseck J.D., Field M.J., Fischer S., Gao J., Guo H., Ha S., Joseph-McCarthy D., Kuchnir L., Kuczera K., Lau F.T.K., Mattos C., Michnick S., Ngo T., Nguyen D.T., Prodhom B., Reiher W.E., Roux B., Schlenkrich M., Smith J.C., Stote R., Straub J., Watanabe M., Wiórkiewicz-Kuczera J., Yin D., Karplus M. An all-atom empirical potential for molecular modeling and dynamics studies of proteins. J.Phys. Chem. B 1998, 102:3586-3616.
27. Mackerell A.D., Feig M., Brooks C.L. Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J.Comput. Chem. 2003, 25:1400-1415.
28. Magotti P., Ricklin D., Qu H., Wu Y.Q., Kaznessis Y.N., Lambris J.D. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J.Mol. Recognit.: JMR 2009, 22:495-505.
29. Mallik B., Katragadda M., Spruce L.A., Carafides C., Tsokos C.G., Morikis D., Lambris J.D. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J.Med. Chem. 2005, 48:274-286.
30. Mallik B., Lambris J.D., Morikis D. Conformational inter-conversion of compstatin probed with molecular dynamics simulations. Proteins 2003, 53:130-141.
31. Mallik B., Morikis D. Development of a quasi-dynamic pharmacophore model for anti-complement peptide analogues. J.Am. Chem. Soc. 2005, 127:10967-10976.
32. Maminishkis A., Chen S., Jalickee S., Banzon T., Shi G., Wang F.E., Ehalt T., Hammer J.A., Miller S.S. Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest. Ophthalmol. Vis. Sci. 2006, 47:3612-3624.
33. Marmorstein R.Q., Joachimiak A., Sprinzl M., Singler P.B. The structural basis for the interaction between L-tryptophan and the Escherichia coli trp aporepressor. J.Biol. Chem. 1987, 262:4922-4927.
34. Morikis D., Assa-Munt N., Sahu A., Lambris J.D. Solution structure of compstatin, a potent complement inhibitor. Prot. Sci. 1998, 7:619-627.
35. Morikis D., Floudas C.A., Lambris J.D. Structure-based integrative computational and experimental approach for the optimization of drug design. Computational Science - Iccs 2005 2005, 680-688. Pt 2.
36. Morikis D., Lambris J.D. Structural aspects and design of low molecular mass complement inhibitors. Biochem. Soc. T 2002, 30:1026-1036.
37. Morikis D., Lambris J.D. Structure, Dynamics, Activity, and Function of Compstatin and Design of More Potent Analogues 2005, Crc Press-Taylor & Francis Group, 6000 Broken Sound Parkway Nw, Ste 300, Boca Raton, Fl 33487-2742 USA.
38. Morikis D., Roy M., Sahu A., Troganis A., Jennings P.A., Tsokos G.C., Lambris J.D. The structural basis of compstatin activity examined by structure-function-based design of peptide analogs and NMR. J.Biol. Chem. 2002, 277:14942-14953.
39. Morikis D., Soulika A.M., Mallik B., Klepeis J.L., Floudas C.A., Lambris J.D. Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. Biochem. Soc. T 2004, 32:28-32.
40. Qu H., Ricklin D., Bai H., Chen H., Reis E.S., Maciejewski M., Tzekou A., DeAngelis R.A., Resuello R.R.G., Lupu F., Barlow P.N., Lambris J.D. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 2013, 218:496-505.
41. Qu H., Ricklin D., Lambris J.D. Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 2009, 47:185-195.
42. Ricklin D., Lambris J.D. Complement-targeted therapeutics. Nat. Biotechnol. 2007, 25:1265-1275.
43. Ricklin D., Lambris J.D. Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 2008, 632:273-292.
44. Rudolf M., Clark M.E., Chimento M.F., Li C.M., Medeiros N.E., Curcio C.A. Prevalence and morphology of druse types in the macula and periphery of eyes with age-related maculopathy. Invest. Ophthalmol. Vis. Sci. 2008, 49:1200-1209.
45. Sahu A., Kay B.K., Lambris J.D. Inhibition of human complement by a C3 binding peptide isolated from a phage displayed random peptide library. J.Immunol. 1996, 157:884-891.
46. Sahu A., Morikis D., Lambris J.D. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol. Immunol. 2003, 39:557-566.
47. Sahu A., Soulika A.M., Morikis D., Spruce L., Moore W.T., Lambris J.D. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin. J.Immunol. 2000, 165:2491-2499.
48. Song M.K., Kim S.Y., Lee J. Understanding the structural characteristics of compstatin by conformational space annealing. Biophys. Chem. 2005, 115:201-207.
49. Soulika A.M., Morikis D., Sarrias M.R., Roy M., Spruce L.A., Sahu A., Lambris J.D. Studies of structure-activity relations of complement inhibitor compstatin. J.Immunol. 2003, 171:1881-1890.
50. Tamamis P., López de Victoria A., Gorham R.D., Bellows-Peterson M.L., Pierou P., Floudas C.A., Morikis D., Archontis G. Molecular dynamics in drug design: new generations of compstatin analogs. Chem. Biol. Drug Des. 2012, 79:703-718.
51. Tamamis P., Morikis D., Floudas C.A., Archontis G. Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations. Proteins 2010, 78:2655-2667.
52. Tamamis P., Pierou P., Mytidou C., Floudas C.A., Morikis D., Archontis G. Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin. Proteins 2011, 79:3166-3179.
53. Tamamis P., Skourtis S.S., Morikis D., Lambris J.D., Archontis G. Conformational analysis of compstatin analogues with molecular dynamics simulations in explicit water. J.Mol. Graph Model 2007, 26:571-580.
54. Valkó K. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. J.Chromatography. A 2004, 1037:299-310.
55. Yehoshua Z., Rosenfeld P.J., Albini T.A. Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures. Semin. Ophthalmol. 2011, 26:167-180.
56. Yesselman J.D., Price D.J., Knight J.L., Brooks C.L. MATCH: an atom-typing toolset for molecular mechanics force fields. J.Comput. Chem. 2012, 33:189-202.
57. Zarbin M.A., Rosenfeld P.J. Pathway-based therapies for age-related macular degeneration an integrated survey of emerging treatment alternatives. Retina-The J. Retin. Vitreous Dis. 2010, 30:1350-1367.